Study shows new once-daily weight-loss pill orforglipron outperforms leading oral semaglutide in patients with type 2 diabetes on weight and A1C reduction
Eli Lilly’s once-daily orforglipron showed greater A1C and weight reduction than oral semaglutide in a 52-week type 2 diabetes trial.